TCRX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer...

Stats
今日成交量	92 052.00
平均成交量	196 857
市值	319.19M
EPS	$0 ( 2024-03-13 )
下一个收益日期	( $-0.250 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.42
ATR14	$0.0240 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Baker Bros. Advisors Lp	Buy	8 851 451	Warrants to purchase Common Stock
2024-04-19	Baker Bros. Advisors Lp	Buy	825 968	Warrants to purchase Common Stock
2024-04-19	Lynx1 Capital Management Lp	Buy	5 000 000	Pre-funded Warrant (right to buy)
2024-02-01	Amello Jason	Buy	750 000	Stock Option (Right to Buy)
2024-01-29	Amello Jason	Buy	0

INSIDER POWER
99.17
Last 93 transactions
Buy: 66 481 256 \| Sell: 5 443 695

音量相关性

長: -0.10 (neutral)

短: -0.69 (moderate negative)

Signal:(43.678) Neutral

TScan Therapeutics, Inc. 相关性

10 最正相关
CRSA	0.871
HALL	0.871
MVBF	0.868
SNCR	0.859
OSMT	0.857
MYNA	0.84
SOUN	0.839
KFRC	0.824
LMFA	0.823
LMNL	0.819

10 最负相关
SLVO	-0.879
BNIXU	-0.864
BMRN	-0.85
ARTNA	-0.848
MRNA	-0.839
FNKO	-0.838
CAMP	-0.836
FNWD	-0.823
AVDX	-0.815

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

TScan Therapeutics, Inc. 相关性 - 货币/商品

0.18
( neutral )

0.16
( neutral )

0.00
( neutral )

0.30
( neutral )

0.06
( neutral )

-0.33
( neutral )

TScan Therapeutics, Inc. 财务报表

Annual	2023
营收:	$21.05M
毛利润:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2023
营收:	$21.05M
毛利润:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2022
营收:	$13.54M
毛利润:	$8.40M (62.05 %)
EPS:	$-2.74

FY	2021
营收:	$10.14M
毛利润:	$0.00 (0.00 %)
EPS:	$-4.17

Financial Reports:

No articles found.

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.